Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

King Altace sNDA Submitted For Five Indications; 4th Quarter Sales Grew 46%

Executive Summary

King submitted an Altace (ramipril) sNDA Jan. 18 for the significant reduction of mortality, myocardial infarction, stroke, revascularization procedures and heart failure in patients at risk for such events.
Advertisement

Related Content

Comparative Hypertensive Trials Preferred Endpoint Is Systolic BP, Cmte Says
Comparative Hypertensive Trials Preferred Endpoint Is Systolic BP, Cmte Says
Altace Will Gain 1,000 Wyeth Reps Through Copromotion Deal
Altace Will Gain 1,000 Wyeth Reps Through Copromotion Deal
King Altace
King Altace
Advertisement
UsernamePublicRestriction

Register

PS035483

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel